IMMUNOSTEM PD-L1 HSPC gene therapy
Altheia Science
What it is
A first-in-human gene-therapy program using a person's own CD34+ hematopoietic stem and progenitor cells, modified ex vivo with a lentiviral vector to express PD-L1 and re-establish immune tolerance in recent-onset T1D.
Editorial review: .
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Preclinical evidence. Benefit in people has not been established.See the linked studies and their populations →
- Benefit or performance
- Efficacy: PD-L1 HSPC restoration was reported to cure autoimmune diabetes in preclinical work, but the human IMMUNOSTEM trial has not started reporting outcomes.[3]
- Important harms and treatment burden
- Safety: Autologous ex vivo lentiviral HSPC therapy is complex and safety is the primary first-in-human question.[1]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: HSPC gene modification could be durable in principle, but long-term engraftment and durable beta-cell protection in people with T1D remain unproven.[1]
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. This speculative assessment includes intended performance or preclinical findings; it does not establish benefit in people.
Default calculation: 15 × 20 + 25 × 12 + 15 × 16 + 20 × 12 + 18 × 20 = 1440; divide by total weight 80. Unrounded weighted result: 18.
PD-L1 HSPC restoration was reported to cure autoimmune diabetes in preclinical work, but the human IMMUNOSTEM trial has not started reporting outcomes.[3]
HSPC gene modification could be durable in principle, but long-term engraftment and durable beta-cell protection in people with T1D remain unproven.[1]
Autologous ex vivo lentiviral HSPC therapy is complex and safety is the primary first-in-human question.[1]
Initial trial is limited to adults 18-40 with recent-onset T1D and residual beta-cell function.[1]
Registered phase 1/2 but still not yet recruiting on ClinicalTrials.gov as of 27 August 2026 — roughly 11 months past its own anticipated August 2025 start. Planned enrolment is 15 at a single Italian site, with primary completion in 2029.[1]
Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.
The full picture
IMMUNOSTEM is not a replacement-cell therapy. It is an immune-reset strategy: repair the patient's own hematopoietic stem/progenitor cells so they express PD-L1, a checkpoint signal meant to restrain autoreactive T cells. If it worked, it could preserve residual beta cells after diagnosis and potentially protect replacement cells later. The caution is equally clear: this is gene-modified autologous cell therapy, at the very beginning of human testing.
The registered phase 1/2 study (NCT06938334) is a single-site trial at Azienda Ospedale-Università Padova in Italy, planning 15 adults aged 18-40 with recent-onset T1D (treated within 180 days of their first insulin), at least two autoantibodies and residual C-peptide, with primary completion scheduled for June 2029. A live registry check on 27 August 2026 found it still listed as not yet recruiting — its own anticipated start date of August 2025 has already slipped by about 11 months, so treat any timeline here as provisional.
Coming soon
ETA · First-in-human phase 1/2 not yet recruiting
- →Open recruitment at Azienda Ospedale-Università Padova (Italy) — anticipated start was August 2025, still not-yet-recruiting as of July 2026 · timing not set
Sources
- [1]IMMUNOSTEM PD-L1 autologous HSPC gene therapy trial (NCT06938334) · Trial registry
- [2]Altheia Science — PD-L1 HSPC technology · Manufacturer
- [3]